AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
Best practices for grounding brand decision-making in insights
In today’s evolving pharmaceutical landscape, harnessing the power of insights is more critical than ever. Integrating primary, secondary, and analytical...